LEADER 01313nam0 22003133i 450 001 VAN0130355 005 20230615022434.675 017 70$2N$a978-3-319-75836-7 100 $a20200729d2018 |0itac50 ba 101 $aeng 102 $aCH 105 $a|||| ||||| 200 1 $aTargeting the DNA Damage Response for Anti-Cancer Therapy$fJohn Pollard, Nicola Curtin editors 210 $aCham$cSpringer$d2018 215 $aix, 401 p.$d24 cm 410 1$1001VAN0111323$12001 $aCancer Drug Discovery and Development$1210 $aNew York$cSpringer 620 $aCH$dCham$3VANL001889 702 1$aCurtin$bNicola$3VANV103858 702 1$aPollard$bJohn$3VANV103857 712 $aHumana $3VANV108434$4650 712 $aSpringer $3VANV108073$4650 801 $aIT$bSOL$c20240614$gRICA 856 4 $uhttps://link.springer.com/book/10.1007/978-3-319-75836-7$zE-book ? Accesso al full-text attraverso riconoscimento IP di Ateneo, proxy e/o Shibboleth 899 $aBIBLIOTECA CENTRO DI SERVIZIO SBA$2VAN15 912 $fN 912 $aVAN0130355 950 $aBIBLIOTECA CENTRO DI SERVIZIO SBA$d15CONS SBA EBOOK 6741 $e15EB 6741 20200729 996 $aTargeting the DNA Damage Response for Anti-Cancer Therapy$91754035 997 $aUNICAMPANIA